Original ArticleUsing Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC)
Under an Elsevier user license
open archive
Key words
Non-small cell lung cancer
Advanced stage
Early stage
Whole genome amplification
Low-volume biopsies
KRAS mutations
CMET mutations
EGFR mutations
p53 mutations
Prognosis
Cited by (0)
Disclosure: The authors declare no conflicts of interest.
Copyright © 2009 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.